Telix Pharmaceuticals

Telix Pharmaceuticals Book Value per Share

The Book Value per Share of Telix Pharmaceuticals (TLX.AX) as of Nov 21, 2026 is 1.23 USD. In the previous year, Book Value per Share was 1.04 USD — a change of 17.69% (higher).

Book Value per Share

1.23USD

YoY

17.69%

Last updated:

Book Value per Share of Telix Pharmaceuticals is 2025 1.23 USD. Book Value per Share of Telix Pharmaceuticals was 2024 1.04 USD. It decreases by 17.69% higher compared to the previous year.

The Telix Pharmaceuticals Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
0.16 USD
Jan 1, 2019
0.21 USD
Jan 1, 2020
0.23 USD
Jan 1, 2021
0.01 USD
Jan 1, 2022
0.15 USD
Jan 1, 2023
0.30 USD
Jan 1, 2024
1.04 USD
Jan 1, 2025
1.23 USD
The Telix Pharmaceuticals Book Value per Share history
YEARBook Value per ShareYoY
1.23USD+17.69%
1.04USD+243.84%
0.30USD+97.83%
0.15USD+2,304.29%
0.01USD-97.27%
0.23USD+12.75%
0.21USD+32.47%
0.16USD+7.33%
0.15USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Book Value per Share of Telix Pharmaceuticals is 1.23 USD in 2025.

Book Value per Share of Telix Pharmaceuticals changed from 1.04 USD to 1.23 USD, representing a 17.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals